A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction
PHASE1CompletedINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
March 31, 1992
Study Completion Date
January 31, 2001
Conditions
Kidney Diseases
Interventions
DRUG
carboxypeptidase-G2
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001298 - A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction | Biotech Hunter | Biotech Hunter